HLB Genex, Inc. (KOSDAQ:187420)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,810.00
+20.00 (0.72%)
At close: Dec 5, 2025
-29.13%
Market Cap 81.87B
Revenue (ttm) 40.95B
Net Income (ttm) -3.28B
Shares Out 29.14M
EPS (ttm) -116.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 49,775
Average Volume 47,854
Open 2,865.00
Previous Close 2,790.00
Day's Range 2,740.00 - 2,865.00
52-Week Range 2,700.00 - 5,830.00
Beta -0.00
RSI 40.54
Earnings Date Nov 14, 2025

About HLB Genex

HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, o... [Read more]

Industry Industrial Organic Chemicals
Founded 2000
Employees 75
Stock Exchange KOSDAQ
Ticker Symbol 187420
Full Company Profile

Financial Performance

In 2024, HLB Genex's revenue was 35.43 billion, an increase of 31.18% compared to the previous year's 27.01 billion. Losses were -18.83 billion, 538.2% more than in 2023.

Financial Statements

News

There is no news available yet.